AnaptysBio Inc (ANAB.OQ)
ANAB.OQ on NASDAQ Stock Exchange Global Select Market
81.25USD
18 Oct 2018
81.25USD
18 Oct 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$81.25
$81.25
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
151,047
151,047
52-wk High
$134.00
$134.00
52-wk Low
$60.80
$60.80
About
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro,... (more)
Overall
| Beta: | -- |
| Market Cap(Mil.): | $725.82 |
| Shares Outstanding(Mil.): | 20.34 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ANAB.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.68 | 33.65 |
| EPS (TTM): | -1.06 | -- | -- |
| ROI: | -23.31 | 0.45 | 14.28 |
| ROE: | -48.33 | 1.37 | 16.00 |
BRIEF-Anaptysbio Qtrly Loss Per Share $0.63
* ANAPTYSBIO ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES
Competitors
| Price | Chg | |
|---|---|---|
| Roche Holding Ltd. (ROG.S) | CHF244.95 | +6.40 |
| Roche Holding Ltd. (RO.S) | CHF245.20 | +5.80 |
| GlaxoSmithKline plc (GSK.L) | 1,557.60 | +47.00 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 7,940.00 | +251.00 |
| Allergy Therapeutics plc (AGY.L) | 17.60 | 0.00 |
| AstraZeneca plc (AZN.L) | 5,934.00 | +56.00 |
| Pfizer Inc. (PFE.N) | $44.69 | +0.69 |
| Regeneron Pharmaceuticals Inc (REGN.OQ) | $392.34 | -2.88 |
| Sanofi SA (SASY.PA) | €77.80 | 0.00 |
| Amgen, Inc. (AMGN.OQ) | $202.86 | +0.14 |
Estimates